Cancer immunology

DGAP-News: Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway

Thursday, March 26, 2020 - 8:01am

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication

Key Points: 
  • DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication
    Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway
    The issuer is solely responsible for the content of this announcement.
  • Both targets are catalytic enzymes that play a key role in an important immunosuppressive pathway - the degradation of tryptophan into kynurenine.
  • Secarna's approach also was shown to be synergistic with one of the clinically most advanced IDO1-specific small molecule inhibitors (epacadostat).
  • The published data show that treatment of cancer cells with LNAplusTM-modified ASOs specific for IDO1 and TDO2 lead to potent target knockdown in vitro.

Society for Immunotherapy of Cancer to Host Leadership Institute Focusing on Professional Development of Women in Cancer Immunotherapy

Tuesday, January 28, 2020 - 3:00pm

The Women in Cancer Immunotherapy Network (WIN) Leadership Institute returns this summer, and will grow to two programs, in Seattle (July 1314) and Chicago (Aug. 34).

Key Points: 
  • The Women in Cancer Immunotherapy Network (WIN) Leadership Institute returns this summer, and will grow to two programs, in Seattle (July 1314) and Chicago (Aug. 34).
  • The one-and-a-half day programs celebrate and empower emerging women leaders in the cancer immunotherapy field.
  • Championed by SITC Immediate Past President Lisa H. Butterfield, PhD, the Women in Cancer Immunotherapy Network (WIN) is a SITC initiative launched in 2017 that has included annual receptions celebrating women in cancer immunotherapy.
  • Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology.

Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston

Tuesday, November 19, 2019 - 1:45pm

Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals.
  • GPR174 deficiency in these mice resulted in significantly reduced tumor growth and improved survival of the animals (p=0.006 in melanoma; p=0.03 in colon cancer) versus normal mice.
  • These findings are being presented today by Marc Gavin, Ph.D., Omeros Director of Immunology, at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts.
  • PS has been shown by Omeros to suppress T-cell activity through GPR174.

Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy

Friday, November 8, 2019 - 1:30pm

Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.
  • Marc Gavin, Ph.D., Omeros Director of Immunology, will present the companys new findings that phosphatidylserine, a product of cell stress and death that is abundant in the tumor microenvironment (TME), directly stimulates GPR174 and attenuates T-cell responses.
  • The data will also feature new findings from animal tumor models, which validate GPR174 inhibition for cancer immunotherapy.
  • Small-molecule inhibitors of GPR174 are part of Omeros proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds.

Intensity Therapeutics' INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology

Wednesday, July 17, 2019 - 1:27pm

We believe this is the first time that the well-known agents comprising INT230-6, cisplatin and vinblastine showed induction of a durable immune activation.

Key Points: 
  • We believe this is the first time that the well-known agents comprising INT230-6, cisplatin and vinblastine showed induction of a durable immune activation.
  • We believe this result is due to the intratumoral delivery mechanisms of the compound, which appears to cause cell death that also releases antigens to initiate an adaptive immune response.
  • Treatment resulted in regression from baseline in 100 percent of tumors and complete response in up to ninety percent of mice.
  • Studies that knocked out the mouse immune cells prevented complete responses, indicating a critical role of immune cells in treatment benefit.

Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy

Tuesday, January 22, 2019 - 12:00pm

The findings were published in two peer-reviewed papers in Cancer Immunology Research, an American Association for Cancer Research publication.

Key Points: 
  • The findings were published in two peer-reviewed papers in Cancer Immunology Research, an American Association for Cancer Research publication.
  • "These are our first scientific publications discussing PVRIG, a new immune checkpoint we discovered computationally, and its inhibitory role within what we have termed the DNAM axis," stated Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.
  • "The publication of these two peer-reviewed papers further validates our understanding of the PVRIG pathway and its importance in cancer immunotherapy.
  • Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Anixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor Immunology and Immunotherapy

Thursday, November 15, 2018 - 12:00pm

The conference is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to treat cancer.

Key Points: 
  • The conference is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden the understanding of ways to harness the immune system to treat cancer.
  • "We are pleased to make our presentation titled, Combining the immunophenotyping of MDSCs and lymphocytes with artificial intelligence (AI) to predict early stage breast cancer, at the AACR Tumor Immunology and Immunotherapy conference.
  • This data is focused on using our Cchek technology to detect breast cancer in its early stages.
  • We recently presented our latest prostate cancer data at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC), and we look forward to now present our latest breast cancer data at this AACR special conference," added Dr. Kumar.

BioInvent Announces Publication of Data in Leading Cancer Journal Immunity

Tuesday, November 13, 2018 - 5:31pm

Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.

Key Points: 
  • Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.
  • This research is the result of a long-standing collaborative effort between the Southampton Antibody and Vaccine Group, Centre for Cancer Immunology, BioInvent and Cancer Research UK, to promote translational research into effective cancer immunotherapies.
  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.

BioInvent Announces Publication of Data in Leading Cancer Journal Immunity

Tuesday, November 13, 2018 - 4:50pm

Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.

Key Points: 
  • Tregs are known to potently suppress anti-tumor immunity, while CD8+ T cells critically contribute to anti-tumor immunity.
  • This research is the result of a long-standing collaborative effort between the Southampton Antibody and Vaccine Group, Centre for Cancer Immunology, BioInvent and Cancer Research UK, to promote translational research into effective cancer immunotherapies.
  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.